Everest Medicines said it has struck an exclusive licence and collaboration with
Travere Therapeutics granting Travere exclusive development and commercial
rights to EVER001 (civorebrutinib) outside Greater China and certain Southeast
Asian countries. Everest will receive a $112.5m upfront payment and is eligible
for up to $1.03bn in development, regulatory and commercial milestone payments
across up to five indications, plus tiered royalties on future annual net sales
ranging from high-single-digit to low-double-digit pct.